Randomized, Double-Blind, Placebo-Controlled Study of Modified Erzhi Granules in the Treatment of Menopause-Related Vulvovaginal Atrophy

Table 1

Baseline parameters in the two groups.

	treatment group	placebo group	p
demographic
n	39	36
Age, years	59.67±3.47	58.53±4.53	0.338
Body mass index, kg/m	24.23±3.45	24.59±3.51	0.726
age of menopause, years	49.43±3.93	49.44±4.25	0.061
Menopause time, years	10.24±5.37	9.09±5.96	0.241
Course of disease, years	1.56±0.88	1.21±1.21	0.979
vaginal health score	9.87±2.33	10.44±2.35	0.245
elasticity	2.18±0.56	2.25±0.55	0.585
moisture	2.00±0.76	2.08±0.73	0.700
pH	1.92±0.66	1.89±0.71	0.810
mucosa	1.95±0.89	2.14±0.72	0.330
discharge	1.82±0.68	2.08±0.73	0.127
Vaginitis score	4.50±1.57	4.58±1.57	0.925
pain	0.87±0.52	0.94±0.63	0.619
painful sexual intercourse	1.18±0.73	1.26±0.81	0.673
itching	1.38±0.75	1.19±0.58	0.276
burning	1.18±0.68	1.06±0.71	0.472
vaginal maturation index
percentage of superficial cells	0.67±1.18	1.06±1.24	0.079
percentage of basal cells	55.23±10.32	53.53±9.95	0.494
female sexual function index	12.78±8.55	12.26±8.39	0.738
desire	2.38±0.76	2.40±0.98	0.841
arousal	1.65±1.66	1.48±1.55	0.710
lubrication	1.92±1.94	1.80±1.90	0.844
orgasm	1.81±1.82	1.58±1.62	0.527
satisfaction	2.79±0.89	3.01±1.01	0.212
pain	2.24±2.15	2.00±1.97	0.431
modified Kupperman Index	22.64±6.38	23.61±6.56	0.531
Sweating, hot flushes	1.08±0.81	1.14±0.80	0.796
Paresthesia	0.85±0.71	1.19±0.82	0.060
Insomnia	1.23±0.78	1.31±0.79	0.849
Nervousness	1.46±0.64	1.44±0.84	0.817
Melancholia	1.00±0.76	0.86±0.83	0.390
Vertigo	0.82±0.76	0.89±0.62	0.589
Fatigue	1.62±0.49	1.58±0.73	0.629
Arthralgia, myalgia	0.79±0.83	0.86±0.76	0.654
Headache	0.90±0.88	1.03±0.81	0.529
Heart palpitation	0.72±0.76	0.67±0.59	0.971
Formication	0.28±0.46	0.28±0.45	0.967
Sexual complaints	1.82±0.64	1.94±0.71	0.257
Urinary tract infection	0.74±0.85	0.56±0.65	0.410